Anna Bryan

CD BioGlyco, a leading provider of glycosylation-related services, is proud to announce the launch of its specialized antibody deglycosylation services, including Hydrolysis of All Fc-Glycans and Hydrolysis of Complex-Type N-Glycans. These services are designed to help pharmaceutical and biotechnology companies better understand and optimize the role of glycosylation in therapeutic antibodies, ultimately leading to more effective biologic drugs.

Glycosylation is a critical modification in therapeutic antibodies, affecting their stability, immune activation, and pharmacokinetics. The two main glycosylation types targeted by CD BioGlyco’s new services—Fc-glycans and complex-type N-glycans—play essential roles in antibody function. By removing or modifying these glycans, CD BioGlyco’s clients can optimize antibody designs for better efficacy and safety profiles in drug development.

“Understanding how glycosylation affects antibody function is a cornerstone of advancing biologic therapeutics,” said Anna, a representative speaker from CD BioGlyco. “Our Hydrolysis of Fc-glycans and Hydrolysis of Complex-Type N-glycans services offer precise, enzyme-based deglycosylation that allows researchers to isolate and study the impact of glycosylation on antibody performance. Whether improving binding affinity or modulating immune responses, these services are critical to optimizing therapeutic antibodies for better patient outcomes.”

Hydrolysis of All Fc-Glycans: Fc-glycans are located in the Fc region of the antibody and play a significant role in modulating immune effector functions, such as antibody-dependent cellular cytotoxicity (ADCC) and complement activation. The Hydrolysis of All Fc-Glycans service enables the removal of these glycan structures, allowing researchers to examine the impact of Fc-glycans on immune modulation and pharmacokinetics. By eliminating these glycans, scientists can study how glycan removal affects antibody effector functions and optimize therapeutic antibodies for improved efficacy.

Hydrolysis of Complex-Type N-Glycans: Complex-type N-glycans are attached to the antibody’s heavy and light chains and are known to influence protein folding, stability, and binding properties. The Hydrolysis of Complex-Type N-Glycans service is designed to remove these specific glycans, enabling researchers to isolate the effects of N-glycosylation on antibody performance. This process helps identify the contribution of complex-type glycans to the functional properties of antibodies and aids in optimizing glycosylation patterns to improve therapeutic performance.

These antibody deglycosylation services are crucial for researchers and biopharmaceutical companies working to fine-tune the glycosylation patterns of therapeutic antibodies, improving the design of monoclonal antibodies (mAbs), bispecific antibodies, and antibody-drug conjugates (ADCs).

In celebration of the New Year, CD BioGlyco is offering a special promotion: enjoy up to 25% off on all products and services, including its new antibody deglycosylation offerings. This limited-time offer is available until January 31, 2025, allowing clients to take advantage of significant savings on essential glycosylation services.

For more information on CD BioGlyco’s antibody deglycosylation services or to take advantage of the New Year sale, visit https://www.bioglyco.com/.